Normal 1–2 ml EDTA blood or 1–2 µg DNA plus tumor material with at least 20% tumor content. Tumor RNA is strongly beneficial and required to confirm expression of candidate neoantigens.
TUMOR DIAGNOSTICS
CancerNeo
Integrates tumor–normal exome data, HLA typing, and tumor RNA expression to prioritize patient-specific HLA class I and II neoantigens and peptide candidates.
Tumor–normal WES/ExomeXtra, HLA typing, whole-transcriptome sequencing, neoantigen prediction, and selection of up to 12 peptide candidates; broad tumor biomarkers are also assessed.
Prioritized HLA class I/II neoantigens, up to 12 peptide candidates, tumor profile, expression support, TMB/MSI/HRD, and relevant molecular findings.
Confirmed for the personalized multi-omic workflow after sample review.
CLINICAL VALUE
Where this test is strongest
✓Personalized rather than fixed-panel design
✓DNA + RNA + HLA integration
✓Up to 12 peptide candidates
✓Broad tumor profile and optional immune/pathology modules
LIMITATIONS
What must remain visible
!This is a specialized design service, not a standard vaccine treatment or guarantee of clinical benefit.
!Requires adequate tumor and normal material; RNA quality affects expression confirmation.
GENE & ANALYTICAL SCOPE
Scope confirmed per case
No fixed gene panel defines the neoantigens; candidates are unique to the patient's tumor. A detailed tumor-profile scope is also generated.
Personalized neoantigensCase-specific analytical scope+
Tumor-specific variants are combined with HLA class I/II binding prediction and RNA-expression evidence; up to 12 peptides are prioritized.
No fixed gene-by-gene list applies to this scope.
Tumor profileCase-specific analytical scope+
More than 700 tumor genes and more than 30 fusion genes in the referenced broad profile, plus TMB, MSI, HRD, infections, CNVs, pharmacogenetics, and CHIP.
No fixed gene-by-gene list applies to this scope.
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.